Amphastar Pharmaceuticals (NASDAQ:AMPH) Second Quarter 2024 Results
Key Financial Results
-
Revenue: US$182.4m (up 25% from 2Q 2023).
-
Net income: US$37.9m (up 45% from 2Q 2023).
-
Profit margin: 21% (up from 18% in 2Q 2023). The increase in margin was driven by higher revenue.
-
EPS: US$0.78 (up from US$0.54 in 2Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Amphastar Pharmaceuticals Revenues Beat Expectations, EPS Falls Short
Revenue exceeded analyst estimates by 4.3%. Earnings per share (EPS) missed analyst estimates by 10%.
Looking ahead, revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 9.4% growth forecast for the Pharmaceuticals industry in the US.
Performance of the American Pharmaceuticals industry.
The company’s shares are up 3.8% from a week ago.
Risk Analysis
We don’t want to rain on the parade too much, but we did also find 1 warning sign for Amphastar Pharmaceuticals that you need to be mindful of.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Source Agencies
